Fri, Oct 31, 2014, 11:14 AM EDT - U.S. Markets close in 4 hrs 46 mins

Recent

% | $
Quotes you view appear here for quick access.

Rockwell Medical, Inc. Message Board

  • crewrider61 crewrider61 Sep 5, 2013 4:54 PM Flag

    Zerenex does what this drug does....

    As well as being a required phosphate binder. This drug will not be part of the bundling in the future. Unfortunately, this agent is too little and too late. Take your profit.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • blehair@gmail.com blehair Sep 5, 2013 6:43 PM Flag

      Few issues. Zerenex has some of the same issues inherent in the current IV iron therapies, such as overburdening patients with too much iron. Further, trial demographic, and more importantly, trial design were completely different because Zerenex is not being assessed for it's iron therapy ability by the FDA.

      IV iron was permitted, which confounds the hell out of iron data in the Zerenex trial, and even with it's permitted use the Hgb improvement vs placebo over the duration of the trial was comparable to SFP which had no supplemental IV iron use.

      Zerenex is a revolutionary drug though, I won't take anything away from their remarkable drug, but SFP is not in competition with it... They are entirely different markets.

      • 2 Replies to blehair
      • Good luck to you, and congrats for today. I am long KERX and had some money in RMTI as well. I missed the big bump today, because I had some money tied up that I was hoping would be available last week, but its still tied up in the TSRX tender. I was going to split it between AMRN and RMTI, but now I may not put it in RMTI anymore since I missed the big bump. I like SFP, but oral Zerenex will still lower phosphates as well as the currently available phosphate binders, but will, no matter if the trials weren't set up to do this or not, increase iron stores. It also doesn't have a lot of the major side effects of IV iron (also avoided by SFP as well). It will decrease the need for SFP. I think SFP is a great drug and there will be a market for it. But I think Zerenex will undoubtedly take away some of the market share from RMTI in the long run, whether it is intended to or not (I don't think it will be intended). They will both take market share from Amgen though, so Amgen may not be too happy about that, but that's the way the cookie crumbles. There is a place in the world for both RMTI and KERX, and I think they both will be profitable, but long term I do think that KERX will be more profitable. Like I said, good luck and I hope both companies are winners.

      • I understand your points. The reality of the situation is that when" bundling", the end result and lowest cost is what matters. If the iron and Hgb are increased, the EPO needed is decreased and phosphate binding is accomplished with one drug, there is no need for other agents. It's all a matter of less is better, in both the number of agents used and the cost. Increasing iron, Hgb and phosphate binding can be accomplished with many agents...or just one...Zerenex. Bam!

    • RMTI is not in direct competition with Kerx

    • Lol you have clearly not done your DD - no part of zenerex has any effect of hemodialysate levels you clown. GO SHORT SOMETHING ELSE TROLL

    • I fully agree !! I own KERX also. Sold RMTI today for a 3.00 gain !

      Sentiment: Strong Sell

 
RMTI
9.03-0.35(-3.73%)11:13 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.